News center
August 1, China, Beijing, Liu Xueliang, deputy secretary of the District Party Committee and district governor, led a team to visit key enterprises of Daxing biomedical Industry Base to investigate the development and construction of pharmaceutical research and development service platform enterprises.
Liu Xueliang first came to the Institute of Materia Medica of the Chinese Academy of Medical Sciences (referred to as the "Institute of Materia Medica") to understand the construction and development of the history museum of Materia Medica. Enter the laboratory, understand the laboratory opening, scientific research instrument sharing management. The institute has 7 provincial and ministerial key laboratories, 5 university level key laboratories and centers, and 7 affiliated enterprises, many of which have settled in Daxing biomedical industry Base, forming a complete industrial chain from new drug discovery, product research and development, results transformation, pilot scale, to industrial production and marketing.
Beijing ShouYan Lab Service Co.,Ltd. (hereinafter referred to as "Beijing Shouyan") is a central laboratory established by SDM Bioservices, providing "one-stop" clinical bioanalysis services for the global pharmaceutical and biomedical industries. Liu Xueliang visited the first research laboratory in Beijing to understand the construction and operation of the laboratory, and talked with the person in charge of the enterprise to understand the development status of the enterprise.
During the field visit, Liu Xueliang learned about the development demands of enterprises face to face and listened to the opinions and suggestions of enterprises. Liu Xueliang pointed out that the life and health industry is the leading industry in Daxing District, and the industrial development space is broad. Pharmaceutical research and development service platform enterprises play an important role in pharmaceutical innovation research and development, transformation of scientific and technological achievements, and is of great significance for promoting the development of the whole industrial chain of biomedicine. Liu Xueliang affirmed the achievements of enterprise development, he encouraged enterprises to firm confidence in development, anchor the synergy goal of production, university and research, play the leading role of leading enterprises, strengthen the linkage cooperation with scientific research institutes and upstream and downstream enterprises of the industrial chain, constantly increase scientific research and innovation, improve the ability to transform scientific and technological achievements, and do a good job in the opening and management of sharing platforms. Gather more high-quality biomedical resources to settle in Daxing.
Liu Xueliang stressed that the park and relevant departments should take the initiative to provide services, sort out the industrial chain, and implement precise policies around regulatory approval, financing support, and clinical transformation. It is necessary to strengthen the integration of resources, increase the publicity of enterprise advantages and achievements, provide support and security for enterprises in personnel training, housing security, etc., as always, create a good industrial development ecology, support the development and growth of pharmaceutical research and development service platform enterprises, create benchmarks, and make the biomedical industry chain and industrial cluster bigger and stronger.
KY-0301 is the world's first nano-dual-anti-ADC developed by Novatim based on its own innovative nano-dual-anti-ADC platform “TPEBEN”.
Beijing Shouyan Lab is certified by NGSP in the United States.
Provide diverse and better treatment options for patients worldwide.
At the intersection of the end of the year, we sincerely invite you to join us in focusing on the shining points of the year, and to look back together and cherish the bright moments that have illuminated our way forward in the past year.
On October 24-25 2024, Dr. Yuwen, CBO and SVP of SDM Bioservices, was invited to attend the 2024 International Biomedical Industry Innovation Beijing Forum co-sponsored by DIA and Beijing Advanced Medical Equipment Industry Innovation Alliance. The forum brings together representatives of global regulators, leading experts in biomedicine, industry leaders and academics to discuss the latest trends and industry innovations in global drug development.
AMWC China 2024 World Congress on Aesthetics and Anti-Aging was successfully carried out in Chengdu on October 18-20, 2024, with medical and aesthetic experts, scholars, and industry practitioners from all over the world participating and presenting their latest achievements.
On July 24, SDM Bioserices and Australia JP Medical Consulting Pty Ltd (hereinafter referred to as "JP Medical Consulting") announced a strategic cooperation. The cooperation aims to make full use of the clinical resources and professional advantages of the two sides in the field of medicine in China and Australia, promote the internationalization of clinical trials and new drug research and development, and provide one-stop services for Chinese biopharmaceutical enterprises in Australian clinical trials.
August 1, China, Beijing, Liu Xueliang, deputy secretary of the District Party Committee and district governor, led a team to visit key enterprises of Daxing biomedical Industry Base to investigate the development and construction of pharmaceutical research and development service platform enterprises.
On the way to further explore and promote the professional development of medical clinical trials, SDM and Tonghua Dongbao jointly successfully held a nine-month "Diabetes Professional CRA Series course".
On July 11-12, 2024, MedDRA MSSO successfully held the fourth offline face-to-face training of 2024 at the Shenyang office of SDM. As the organizer of this event, SM gathered together with more than 40 experts from various fields such as CRO, pharmaceutical companies and partners, including medical coders, data management and statistics, drug safety/pharmacovigilance, medical writers and other modules.
On July 3, 2024, SDM Bioservices and Shanghai Ruiningkang Bio-Pharmaceutical Technology Development Co., LTD. (" Ruiningkang Bio ") reached a strategic cooperation to work together to help innovative drugs in the quantitative pharmacology, dose exploration level, and promote more innovative drugs with global competitiveness to the market.
On November 21, 2023, Beijing Kangle Guard Biotechnology Co., Ltd. is affiliated with Muhammadiyah University Malang, Indonesia (at) to start the "restructuring nine price 6/11/16/18/31/33/45/52/58) human papilloma virus (HPV) vaccine (e. coli) phase III clinical trials into the group of vaccination. As a CRO focused on vaccine clinical trials, Shanghai SDM undertook the phase III clinical study of the vaccine project in Indonesia, responsible for project management, data management, biostatistical analysis, pharmacovigilance and other important work of the project.
The laboratories operated by SDM in the North and South have their own specialties and technical advantages. Among them, Beijing Shouyan, with several P2 and P2+ laboratories and complete PCR testing facilities, is one of the few testing organizations in China focusing on bioanalysis of vaccines and traditional Chinese medicines; Hangzhou Amador focuses on XDC, macromolecules, and CGT, etc., and provides one-stop bioanalytical services for ADC drugs, which is a technological leader in the industry.
Meiji has advanced its oral paclitaxel softgel capsule, MJC-001, to clinical trial stage. With support from SDM Bioservices, Meiji received FDA clearance for its Investigational New Drug (IND) application, positioning it among the leading developers of oral paclitaxel formulations.
Listen to Dr. Liping Shen: Innovating Vaccine Bioanalysis for Change
KY-001 is an oral small-molecule inhibitor targeting the YAP/TAZ-TEAD interaction in the Hippo pathway with a proposed indication for advanced solid tumors driven by Hippo dysregulation.
Get in touch with SDM experts for your questions or comments and a member of our team will get back to you directly.
Let's Start a Conversation
